Sclerodermoid chronic graft-versus-host disease (sGVHD) is a well-known complication in patients with a long history of chronic GVHD. Pulmonary involvement in chronic GVHD presents typically as bronchiolitis obliterans (BO). Pulmonary fibrosis after allogeneic hematopoietic stem cell transplantation (HSCT) is presumed to be caused by the long-term toxicity of the conditioning regimen or the result of lung injury elicited predominantly by viral infections or GVHD. We present two patients with late onset pulmonary fibrosis associated with moderate sGVHD of the skin after HSCT. At the initial diagnosis of chronic GVHD both patients presented with symptoms of interstitial pneumonia. Years later both patients developed moderate to severe interstitial pulmonary fibrosis in association with sGVHD. One patient showed additional clinical and histological signs of BO. While one patient responded to increased immunosuppression including total nodal irradiation (1 Gy), the other patient died due to complications related to pulmonary fibrosis. Bone Marrow Transplantation (2002) 29, 357-360. DOI: 10.1038/sj/bmt/1703386 Keywords: bone marrow transplantation; lung fibrosis; graft-versus-host disease; progressive systemic sclerosis; bronchiolitis obliterans; total nodal irradiation Sclerodermoid chronic GVHD (sGVHD) is a well-known late complication in patients with chronic GVHD.
layer with loss of dermal vascularization, and atrophy of the epidermis. [3] [4] [5] Mucosal involvement causes dryness and atrophy of the oral mucosa and motility disorders of the esophagus and stomach.
Progressive systemic sclerosis typically affects the kidneys and the lungs with development of alveolitis and pulmonary fibrosis. 5 However, pulmonary or renal involvement have not been reported in sGVHD. In chronic GVHD pulmonary changes are well known. Bronchiolitis obliterans (BO) is the typical and threatening pulmonary manifestation of chronic GVHD with progressive obstruction of the small bronchioles due to proliferation of the peribronchiolar tissue. [6] [7] [8] [9] [10] [11] The occurrence of pulmonary fibrosis is mainly considered a manifestation of late toxicity of total body irradiation or chemotherapy during conditioning for allogeneic stem cell transplantation or the result of interstitial pneumonitis (IP) mainly due to viral infections or acute GVHD. [12] [13] Here, we report two patients with sGVHD and late onset progressive pulmonary fibrosis.
Patients

Patient 1
A 32-year-old male with a 15 pack-year smoking history received a peripheral stem cell graft from his HLA-identical sister for T-ALL in 2nd CR, after conditioning with TBI (12 Gy in six fractions with shielding of the lung, total pulmonary dose 10 Gy) and cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2. Patient and donor were CMVnegative by serology. GVHD prophylaxis consisted of cyclosporine A (CsA), MTX and prednisone. On day 90, the patient developed primary extensive chronic GVHD of the skin, oral mucosa, salivary glands and liver. At time of diagnosis he was dyspneic and thoracic computed tomography (t-CT) yielded typical signs of IP. Bronchoalveolar lavage revealed lymphocytic alveolitis (lymphocytes 65%, neutrophils 4%, eosinophils 2%) without signs of alveolar hemorrhage. Microbiological studies inclusive of pneumocystis carinii and CMV were negative. Because of the diagnosis of extensive chronic GVHD he was changed from CsA to FK 506 and placed on mycophenolate mofetil
Bone Marrow Transplantation (MMF) and methylprednisone 1 mg/kg/day. The IP improved clinically, and the pulmonary changes resolved as estimated by high resolution t-CT. Immunosuppressive treatment resulted in complete remission of the chronic GVHD symptoms. Methylprednisone was stopped on day 270. Further reduction in immunosuppression resulted in a reappearance of the active chronic GVHD of the skin, liver and oral mucosa and the patient remained on FK 506 and MMF. Twenty-nine months after PBSCT, he started to develop cutaneous signs of sGVHD with patchy sclerosis of the skin. Four months later pulmonary function tests (PFTs) showed mixed obstructive and mild restrictive lung disease ( Table 1) . Seven months later, the patient showed progressive sclerodermoid changes of the skin. At the same time, he developed shortness of breath with progressive reduction in vital capacity (VC), and diffusion capacity (TLCO/VA) and moderate obstruction on PFTs (40 months post PBSCT). Pulmonary restriction was not related to the sclerodermoid skin changes since the chest area was not involved. t-CT revealed nodular reticular sclerosis in both upper lobes. Bronchoalveolar lavage revealed a lymphocytosis (68%) without eosinophils. Transbronchial biopsy showed a focal non-specific granulating inflammation. The serum IgG was elevated at 28.2 g/l. Autoantibody screening revealed ANA-antibodies at a titer of 1:640. The 52 kDa anti-SS-A was positive and 60KD anti-SS-A was negative. At this time FK 506 was changed back to CsA, whereas MMF was continued. One month later the patient stopped taking CsA and MMF. This caused a severe progression of the skin sGVHD. Pulmonary changes progressed, with further increase of shortness of breath, as well as signs of IP on t-CT. Bronchoalveolar lavage confirmed the previously diagnosed lymphocytic alveolitis. Histology showed interstitial fibrosis associated with a lymphocytic infiltrate, as well as a lymphocytic infiltrate with proliferation of fibroblasts, and fibrosis of the small bronchioli reflecting a mixture of fibrosing alveolitis and BO (Figure 1 ). In addition serum analysis revealed a mild elevation of TNF alpha (2.5× the upper normal range) and moderate elevation of IL-2R (5× the upper normal range). PFTs revealed progressive restrictive changes, as well as moderate obstruction. At this time the patient was placed on FK 506 and prednisone 1 mg/kg every other day. Immunosuppressive treatment resulted in an improvement in the obstruction, but further decline of the TLCO/VA (month 46). At this VC = vital capacity; TLC = total lung capacity; FEV1 = forced expiratory volume in 1 s; MEF 50 = mean expiratory flow rate at 50% of VC; DLCO/VA = diffusing capacity of the lung for carbon monoxide corrected by the alveolar volume; TLI = total nodal irradiation; NA = not available. time total nodal irradiation to 1 Gy was given, resulting in an improvement in the skin changes and stabilization of the pulmonary function despite cessation of steroids.
Patient 2
A 39-year-old female received a bone marrow graft from her HLA-DQ mismatched sister, for AML FAB M2 in 1st CR after conditioning with busulfan 4 mg/kg p.o. in divided doses for 4 days daily (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2. Posttransplant immunosuppression consisted of CsA, MTX and prednisone. The patient was CMV-negative before BMT and the donor was CMV IgG-positive. Acute GVHD grade 1 of the skin occurred on day 16 and resolved with an increased dose of prednisone. On day 155 the patient developed extensive GVHD of the skin and oral mucosa, which was initially treated with low-dose steroids, CsA and azathioprine. Seven months post BMT, she developed moderate IP most likely due to CMV infection. Treatment with gancyclovir, immunoglobulins, sulfonamides, and highdose steroids resulted in a clinical remission, but a decreased TLCO/VA and VC remained. Due to persisting symptoms of chronic GVHD she remained on low-dose steroids and azathioprine. The first sclerodermoid changes of the skin appeared 2 years after BMT. The course was complicated by repeated upper airway infections and one episode of bacterial pneumonia. Sixty-four months post BMT, the patient consulted the transplant center with spontaneous bilateral pneumothorax due to severe pulmonary fibrosis ( Figure 2 ) and moderate active sGVHD involving the skin, oral mucosa, salivary and lacrimal glands. PFTs showed severe restriction and moderate decrease in TLCO/VA without signs of obstruction. Serum IgG was in the upper normal range. Autoantibody screening remained negative. Bronchoalveolar lavage revealed 70% macrophages, 20% lymphocytes, 6% neutrophils and 2% eosinophils. Immunosuppression was restarted with FK506, MMF and methylprednisolone. Suction chest tube drainage was sited and the patient improved. PFTs showed an increase in VC (Table 2 ). After 14 days of drainage the patient underwent a surgical thoracotomy due to persistence of a pleuropulmonary air leak. She died 2 days after surgery due to extensive cerebral infarction of unknown etiology.
Discussion
sGVHD and long-term toxicity of the conditioning regimen are the main late effects of allogeneic hematopoietic stem cell transplantation and significantly contribute to the ultimate clinical outcome. One of the late effects of the conditioning regimen is pulmonary fibrosis resulting from VC = vital capacity; TLC = total lung capacity; FEV1 = forced expiratory volume in 1 s; MEF 50 = mean expiratory flow rate at 50% of VC; DLCO/VA = diffusing capacity of the lung for carbon monoxide corrected by the alveolar volume; TLI = total nodal irradiation; NA = not available.
Bone Marrow Transplantation toxicity from total body irradiation or busulfan. 14 Pulmonary fibrosis associated with chronic GVHD has been occasionally reported, but an association with sGVHD has not been described to date. 1, 5 In the cases reported, both patients developed signs of interstitial pulmonary changes simultaneously with clinical progression of sGVHD of the skin years after allogeneic stem cell transplantation. Both patients had high serum IgG concentrations contrasting with the low IgG levels associated with bronchiolitis obliterans and lichenoid chronic GVHD. 6 In addition, patient 1 showed the presence of autoreactive antinuclear antibodies (52kD SS-A, titer 1:640). Chronic GVHD has been repeatedly associated with the presence of autoreactive antibodies. 15, 16 In patient 1, the association between sGVHD and pulmonary changes can be demonstrated by the close relation between the course of immunosuppression, sclerodermoid skin changes, PFTs, cytology of the bronchoalveolar lavage and histology. The presence of a lymphocytic alveolitis in patient 2 combined with severe extensive sGVHD 64 months post BMT is also indicative of an association with sGVHD.
Although the simultaneous late occurrence of sGVHD and pulmonary fibrosis may be a sign of pulmonary involvement by sGVHD, other causes of pulmonary fibrosis cannot be excluded. Both patients received conditioning regimens which have been associated with pulmonary fibrosis. 17 In addition, both patients had clinical acute episodes with interstitial pulmonary changes. Patient 2 had IP most likely due to CMV. Patient 1 showed signs of IP at the time of onset of extensive chronic GVHD in the absence of other causes of IP. Since bronchoalveolar lavage showed a lymphocytosis, pulmonary involvement by chronic GVHD was very likely the cause of the IP in this patient. In addition, the withdrawal of immunosuppression resulted in a reappearance of symptoms indicative of IP, and an increase in obstruction. We believe that the combination of restrictive and obstructive changes is most likely due to a mixture of IP and BO in patient 1. The elevation of IL-2R and TNF-alpha detected in the serum of patient 1 at the time of withdrawal of immunsuppression reflects a Th-1-associated inflammatory process. 18 Symptoms of IP responding to immunosuppression have been described in chronic GVHD. [19] [20] [21] [22] [23] [24] Both patients had repeated airway infections, which are common in patients with chronic GVHD and which may have caused damage to the airways, increasing the obstruc-tive lung disease in patient 1 in combination with nicotine abuse. 13 An additional crucial factor in patient 2 may have been insufficient immunosuppression in the face of active chronic GVHD and progressive pulmonary fibrosis (lost to follow-up).
In conclusion, pulmonary fibrosis may be a manifestation of sGVHD. Other factors such as long-term toxicity of the conditioning regimen, and late fibrosis due to IP are cofactors which might lead to severe pulmonary fibrosis, and cause significant morbidity and mortality.
